Using Voice Recordings to Monitor Neurotoxicity in Adults Receiving CAR T-Cell Therapy for Non-Hodgkin Lymphoma or Multiple Myeloma

What this Trial Is About

Researchers are studying whether voice recordings and neurological assessments can be a practical way to monitor for immune effector cell-associated neurotoxicity syndrome ICANS in people with non-Hodgkin lymphoma or multiple myeloma who are receiving CAR T-cell therapy. The study aims to measure feasibility by tracking how many participants join and complete the assessments. Participants will provide voice recordings at baseline before CAR T-cell infusion, twice daily from Day 0 through Day 10, and, if ICANS develops, twice daily until three days after symptoms resolve. A final recording will be collected on Day 30. Neurologic assessments will also be performed daily during this period. These data collection tasks are done using a smartphone application. Participants will perform twice daily voice recordings and daily neurologic assessments using their smartphones. Researchers will collect and analyze voice data and neurocognitive assessments over 30 days after baseline. The study focuses on feasibility by monitoring enrollment and completion rates. Participation lasts at least 30 days, during which safety and feasibility of using voice as a digital biomarker will be evaluated.

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy